High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation in Relapsed or Refractory Primary CNS Lymphoma: A Retrospective Monocentric Analysis of Long-Term Outcome, Prognostic Factors, and Toxicity.

ABSTRACT: High-dose chemotherapy with autologous stem cell transplantation (HCT-ASCT) is reportedly an effective treatment strategy in relapsed or refractory primary CNS lymphoma (r/r PCNSL); however, only selected patients are eligible for this treatment. We retrospectively analyzed outcome, prognostic factors, and toxicity in 59 patients with r/r PCNSL planned to receive HCT-ASCT at our institution between January 2005 and December 2021 (n = 33 < 65 years; n = 26 ≥ 65 years). Median follow-up was 65 months (95% CI 21-109). Median age was 63 years (range 29-76), median Karnofsky performance score (KPS) was 80 (range 30-100). In the entire cohort of 59 patients, median overall survival (OS) was 14 months (95% CI 0-37). In 50/59 (84.7%) patients who completed HCT-ASCT, median progres

SUBMITTER: Seidel S 

PROVIDER: S-EPMC9106040 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature